Retinopathy of prematurity: Preferred practice patterns among pediatric ophthalmologists

Samiksha Fouzdar Jain, Helen H. Song, Shaza N. Al-Holou, Linda A. Morgan, Donny W Suh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: The treatment of retinopathy of prematurity (ROP) is not standardized and can vary significantly between providers. This study aims to determine preferred practices in treating ROP by globally surveying pediatric ophthalmologists.Methods: Between January and February 2017, an international pediatric ophthalmology interest group was invited to complete an anonymous survey of 18 questions. The main objectives were to determine the preferred first line of treatment for ROP, the preferred dosage of intravitreal bevacizumab (IVB) used, and the outcome and possible complications following bevacizumab injection. Results: Out of 101 pediatric ophthalmologists, 72 (71.8%) stated that they had direct involvement in the treatment of ROP. When presented with type 1 ROP which requires treatment, 69 ophthalmologists (68.3%) stated that they prefer laser treatment over bevacizumab, and 33 ophthalmologists (32.7%) stated they would recommend bevacizumab as a first choice. Ninety-three ophthalmologists (92.1%) reported the success of 1 laser treatment between 75% and 100%, and 35 ophthalmologists (34.7%) perceive bevacizumab to be 75%-100% successful. Half dose of adult-prescribed bevacizumab at 0.625 mg/0.05 mL was preferred by 47 of the ophthalmologists (46.5%). No cases of endophthalmitis were reported with intravitreal injection. Conclusion: Laser photoablation remains the preferred mode of treatment for ROP among surveyed ophthalmologists across the world. Though bevacizumab is currently being used, this form of treatment is not as common, primarily due to the unknown safety profile and potential long-term ramifications of the drug.

Original languageEnglish (US)
Pages (from-to)1003-1009
Number of pages7
JournalClinical Ophthalmology
Volume12
DOIs
StatePublished - May 28 2018

Fingerprint

Retinopathy of Prematurity
Pediatrics
Lasers
Therapeutics
Intravitreal Injections
Public Opinion
Endophthalmitis
Ophthalmologists
Ophthalmology
Bevacizumab
Safety
Injections

Keywords

  • Intravitreal bevacizumab
  • Laser photoablation
  • Neonatal intensive care unit
  • Retinopathy of prematurity

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Retinopathy of prematurity : Preferred practice patterns among pediatric ophthalmologists. / Fouzdar Jain, Samiksha; Song, Helen H.; Al-Holou, Shaza N.; Morgan, Linda A.; Suh, Donny W.

In: Clinical Ophthalmology, Vol. 12, 28.05.2018, p. 1003-1009.

Research output: Contribution to journalArticle

Fouzdar Jain, Samiksha ; Song, Helen H. ; Al-Holou, Shaza N. ; Morgan, Linda A. ; Suh, Donny W. / Retinopathy of prematurity : Preferred practice patterns among pediatric ophthalmologists. In: Clinical Ophthalmology. 2018 ; Vol. 12. pp. 1003-1009.
@article{add923b4ee534beaba6d9d84da36a52e,
title = "Retinopathy of prematurity: Preferred practice patterns among pediatric ophthalmologists",
abstract = "Purpose: The treatment of retinopathy of prematurity (ROP) is not standardized and can vary significantly between providers. This study aims to determine preferred practices in treating ROP by globally surveying pediatric ophthalmologists.Methods: Between January and February 2017, an international pediatric ophthalmology interest group was invited to complete an anonymous survey of 18 questions. The main objectives were to determine the preferred first line of treatment for ROP, the preferred dosage of intravitreal bevacizumab (IVB) used, and the outcome and possible complications following bevacizumab injection. Results: Out of 101 pediatric ophthalmologists, 72 (71.8{\%}) stated that they had direct involvement in the treatment of ROP. When presented with type 1 ROP which requires treatment, 69 ophthalmologists (68.3{\%}) stated that they prefer laser treatment over bevacizumab, and 33 ophthalmologists (32.7{\%}) stated they would recommend bevacizumab as a first choice. Ninety-three ophthalmologists (92.1{\%}) reported the success of 1 laser treatment between 75{\%} and 100{\%}, and 35 ophthalmologists (34.7{\%}) perceive bevacizumab to be 75{\%}-100{\%} successful. Half dose of adult-prescribed bevacizumab at 0.625 mg/0.05 mL was preferred by 47 of the ophthalmologists (46.5{\%}). No cases of endophthalmitis were reported with intravitreal injection. Conclusion: Laser photoablation remains the preferred mode of treatment for ROP among surveyed ophthalmologists across the world. Though bevacizumab is currently being used, this form of treatment is not as common, primarily due to the unknown safety profile and potential long-term ramifications of the drug.",
keywords = "Intravitreal bevacizumab, Laser photoablation, Neonatal intensive care unit, Retinopathy of prematurity",
author = "{Fouzdar Jain}, Samiksha and Song, {Helen H.} and Al-Holou, {Shaza N.} and Morgan, {Linda A.} and Suh, {Donny W}",
year = "2018",
month = "5",
day = "28",
doi = "10.2147/OPTH.S161504",
language = "English (US)",
volume = "12",
pages = "1003--1009",
journal = "Clinical Ophthalmology",
issn = "1177-5467",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Retinopathy of prematurity

T2 - Preferred practice patterns among pediatric ophthalmologists

AU - Fouzdar Jain, Samiksha

AU - Song, Helen H.

AU - Al-Holou, Shaza N.

AU - Morgan, Linda A.

AU - Suh, Donny W

PY - 2018/5/28

Y1 - 2018/5/28

N2 - Purpose: The treatment of retinopathy of prematurity (ROP) is not standardized and can vary significantly between providers. This study aims to determine preferred practices in treating ROP by globally surveying pediatric ophthalmologists.Methods: Between January and February 2017, an international pediatric ophthalmology interest group was invited to complete an anonymous survey of 18 questions. The main objectives were to determine the preferred first line of treatment for ROP, the preferred dosage of intravitreal bevacizumab (IVB) used, and the outcome and possible complications following bevacizumab injection. Results: Out of 101 pediatric ophthalmologists, 72 (71.8%) stated that they had direct involvement in the treatment of ROP. When presented with type 1 ROP which requires treatment, 69 ophthalmologists (68.3%) stated that they prefer laser treatment over bevacizumab, and 33 ophthalmologists (32.7%) stated they would recommend bevacizumab as a first choice. Ninety-three ophthalmologists (92.1%) reported the success of 1 laser treatment between 75% and 100%, and 35 ophthalmologists (34.7%) perceive bevacizumab to be 75%-100% successful. Half dose of adult-prescribed bevacizumab at 0.625 mg/0.05 mL was preferred by 47 of the ophthalmologists (46.5%). No cases of endophthalmitis were reported with intravitreal injection. Conclusion: Laser photoablation remains the preferred mode of treatment for ROP among surveyed ophthalmologists across the world. Though bevacizumab is currently being used, this form of treatment is not as common, primarily due to the unknown safety profile and potential long-term ramifications of the drug.

AB - Purpose: The treatment of retinopathy of prematurity (ROP) is not standardized and can vary significantly between providers. This study aims to determine preferred practices in treating ROP by globally surveying pediatric ophthalmologists.Methods: Between January and February 2017, an international pediatric ophthalmology interest group was invited to complete an anonymous survey of 18 questions. The main objectives were to determine the preferred first line of treatment for ROP, the preferred dosage of intravitreal bevacizumab (IVB) used, and the outcome and possible complications following bevacizumab injection. Results: Out of 101 pediatric ophthalmologists, 72 (71.8%) stated that they had direct involvement in the treatment of ROP. When presented with type 1 ROP which requires treatment, 69 ophthalmologists (68.3%) stated that they prefer laser treatment over bevacizumab, and 33 ophthalmologists (32.7%) stated they would recommend bevacizumab as a first choice. Ninety-three ophthalmologists (92.1%) reported the success of 1 laser treatment between 75% and 100%, and 35 ophthalmologists (34.7%) perceive bevacizumab to be 75%-100% successful. Half dose of adult-prescribed bevacizumab at 0.625 mg/0.05 mL was preferred by 47 of the ophthalmologists (46.5%). No cases of endophthalmitis were reported with intravitreal injection. Conclusion: Laser photoablation remains the preferred mode of treatment for ROP among surveyed ophthalmologists across the world. Though bevacizumab is currently being used, this form of treatment is not as common, primarily due to the unknown safety profile and potential long-term ramifications of the drug.

KW - Intravitreal bevacizumab

KW - Laser photoablation

KW - Neonatal intensive care unit

KW - Retinopathy of prematurity

UR - http://www.scopus.com/inward/record.url?scp=85047993302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047993302&partnerID=8YFLogxK

U2 - 10.2147/OPTH.S161504

DO - 10.2147/OPTH.S161504

M3 - Article

C2 - 29881255

AN - SCOPUS:85047993302

VL - 12

SP - 1003

EP - 1009

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

ER -